Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

Novel leukemia therapy successfully eradicates measurable residual disease

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

7 Jul 2026

Gene fusion patterns refine classification of rare acute leukemias

Acute leukemias with chimeric fusion genes involving FET (FUS, EWSR1, and TAF15) family proteins and ETS (E26 transformation-specific)-like transcription factors often present with unique clinical and pathological characteristics.

27 Jun 2026

New FUSILLI tool improves gene fusion detection in pediatric leukemia

Researchers have introduced a novel diagnostics method that can more sensitively detect gene fusions in B-cell acute lymphoblastic leukemia (B-ALL), the most common type of pediatric cancer, compared to other publicly available fusion detection algorithms.

15 May 2026

Scientists develop a superior diagnostic tool to spot hidden gene fusions in pediatric cancer

Researchers have introduced a novel diagnostic method that can more sensitively detect gene fusions in B-cell acute lymphoblastic leukemia (B-ALL), the most common type of pediatric cancer, compared to other publicly available fusion detection algorithms.

14 May 2026

New CAR T cell design boosts persistence and reduces toxicity

CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting benefit – often because the infused cells fail to expand or persist.

30 Apr 2026

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors effectively, or become exhausted. The review synthesizes 44 clinical scRNA-seq studies involving 500 patients and highlights how exhaustion, memory, cytotoxicity, clonal diversity, and metabolism may shape CAR-T responses.

30 Apr 2026

Early life exposure to PFAS associated with common childhood leukemia

Early exposure to PFAS, a group of widely used compounds known as "forever chemicals," was associated with a higher risk of acute lymphoblastic leukemia, the most common childhood cancer, according to University of California, Irvine Joe C. Wen School of Population & Public Health researchers.

27 Apr 2026

OICR funds four Ontario teams to develop next-generation cancer therapies

Better cancer care depends on better treatment options. That's why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumors, have reduced side effects, and make cancer less likely to return.

9 Apr 2026

New clinical guidelines address blood clot prevention in pediatric patients

The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) released comprehensive clinical practice guidelines on anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism (VTE).

8 Apr 2026

Future CAR therapy expands beyond T cells to treat diverse diseases

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

8 Apr 2026

New approach helps immune cells find and attack solid tumors

A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine researchers.

24 Mar 2026

ASH releases new guidelines for treating leukemia in adolescents and young adults

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population.

12 Feb 2026

Case report examines potential cancer risks after mRNA vaccination

A new case report was published in Volume 17 of Oncotarget on February 6, 2026, titled "Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms."

12 Feb 2026

FDA label update expands CAR T access for primary CNS lymphoma

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord.

9 Feb 2026

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study.

7 Dec 2025

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation.

7 Dec 2025

Many families of children with leukemia face significant financial hardship during treatment

Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child's treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities.

7 Dec 2025

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

Adult patients with an aggressive form of leukemia will be able to receive a breakthrough immunotherapy, which was invented by UCL researchers, on the NHS within weeks following approval for use by the National Institute for Health and Care Excellence (NICE).

27 Nov 2025

Young donor age proves critical for survival after stem cell transplantation

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT).

21 Nov 2025

Acute Lymphoblastic Leukemia News and Research

Further Reading

Novel leukemia therapy successfully eradicates measurable residual disease

Gene fusion patterns refine classification of rare acute leukemias

New FUSILLI tool improves gene fusion detection in pediatric leukemia

Scientists develop a superior diagnostic tool to spot hidden gene fusions in pediatric cancer

New CAR T cell design boosts persistence and reduces toxicity

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Early life exposure to PFAS associated with common childhood leukemia

OICR funds four Ontario teams to develop next-generation cancer therapies

New clinical guidelines address blood clot prevention in pediatric patients

Future CAR therapy expands beyond T cells to treat diverse diseases

New approach helps immune cells find and attack solid tumors

ASH releases new guidelines for treating leukemia in adolescents and young adults

Case report examines potential cancer risks after mRNA vaccination

FDA label update expands CAR T access for primary CNS lymphoma

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

Many families of children with leukemia face significant financial hardship during treatment

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

Young donor age proves critical for survival after stem cell transplantation

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News